Dry Eye
Conditions
Interventions
Experimental group:Administer perfluorohexyloctane eye drops, 4 times daily for 8 weeks.
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Gender unrestricted, age between 18 and 70 years old; 2. Diagnosis of glaucoma, including primary open-angle glaucoma or primary angle-closure glaucoma; 3. Currently undergoing topical treatment with glaucoma medications for at least 3 months; 4.According to the "Chinese Dry Eye Expert Consensus: Examination and Diagnosis (2020)," meets the diagnostic criteria for dry eye and is classified as mild or moderate dry eye. ?Mild:? No significant ocular surface damage signs on slit-lamp examination (corneal fluorescein staining =2 seconds. ?Moderate:? Corneal damage range does not exceed 2 quadrants and/or corneal fluorescein staining >=5 points but =2 seconds. [Meets any of the following: (1) Patient has dry eye-related symptoms (Chinese Dry Eye Questionnaire score >=7 or OSDI >=13), with 2s =7 or OSDI >=13), with 5s =5 points but <30 points and/or corneal damage range <=2 quadrants.] 5. Meets the clinical diagnosis of drug-related dry eye, i.e.: (1) No history of dry eye before using anti-glaucoma medications; (2) Dry eye symptoms appear after topical or systemic medication; (3) Dry eye symptoms correlate with drug dosage and duration; (4) Symptoms usually improve or resolve after discontinuation. 6. The participant or legal guardian has been informed of the study's nature, understands the protocol's requirements, can ensure compliance, and has signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Presence of clinically significant abnormal findings on slit-lamp examination, anatomical abnormalities of the eyelids, intraocular surgery within 12 months or eyelid surgery within 6 months, or secondary dry eye due to surgery; ocular pemphigoid; neurotrophic keratoconjunctivitis. 2. Participants who require wearing corneal contact lenses before the end of the study. 3. Participants with persistent ocular or systemic infections or other serious comorbidities, whom the investigator deems unsuitable for perfluorohexyloctane treatment. 4. Participants who are likely to be non-compliant with the study protocol (including follow-up), such as those with mental disorders, alcoholism, or drug abuse. 5. Other situations deemed by the investigator as unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Corneal Fluorescein Staining Score; | — |
Countries
China
Contacts
Public ContactShaozhen Zhao
Tianjin Medical University Eye Hospital
Outcome results
None listed